Iran Press/ Iran News: Speaking at the unveiling ceremony of COVID-19 therapy trials, including Favipiravir, Remdesivir, and vaccine, which have been produced by Actover Pharmaceutical Company, Alireza Zali stressed that achievements of Iran’s medicine production sector are not comparable with before.
Pointing to Iran’s problems in providing commodities due to currency challenges, he noted: “We must try to provide a long-run map for future diseases like Asthma or Chronic Obstructive Pulmonary Diseases (COPD) as well as various types of cancers; therefore, the therapy trials must be evaluated and monitored.
"There is also a need for investing in the therapies which are changing since there are changes in Iranians' lifestyles and diets," He added.
"COVID-19 is so complicated and its eradication in the world yet seems impossible," Alireza Zali said, adding: "Coronavirus is rapidly mutating as recently seen in Africa and the UK, and next waves are expected to start.
"That is the reason why Iran stresses COVID-19 vaccine production to cut the disease's chain and contain its outbreak," Alireza Zali said.
Actover company has produced 30 million vials of Favipiravir tablets, disinfectants, and more than 600,000 vials of Remedicavir since the coronavirus outbreak to meet the country's needs.
It is expected that Iran's Food and Drug Administration issues the license to produce the Covid-19 vaccine in the near future.
Over 6 million patients use Actover company's medical products. The company is cooperating with aptly famous global companies like Ferrer, HETERO, Rubio, KAKA, and Merck.
207/205
Read More:
Establishment of district-based supervisory HQ in Tehran for fighting Coronavirus
Armed Forces provided many facilities to combat Covid-19: Official
